These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23207142)

  • 21. [Retreatment with peginterferon plus ribavirin in chronic hepatitis C patients: our own experiences].
    Roznovský L; Orságová I; Petrousová L; Mrázek J; Kloudová A; Kabieszová L; Kůrková J; Pospísek M
    Klin Mikrobiol Infekc Lek; 2010 Apr; 16(2):73-5. PubMed ID: 20503159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Peginterferon-alpha and ribavirin combination therapy in chronic hepatitis C].
    Han KH; Yoon YH
    Korean J Hepatol; 2004 Jun; 10(2):81-7. PubMed ID: 15218341
    [No Abstract]   [Full Text] [Related]  

  • 23. [Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: a comparative study].
    Kim JI; Kim SH; Lee BS; Lee HY; Lee TH; Kang YW; Lee HIe; Kim AN; Nam SW; Park BC; Chae HB; Kim SB; Song IH; Park JY; Kim HS
    Korean J Hepatol; 2008 Dec; 14(4):493-502. PubMed ID: 19119244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin.
    Rossignol JF; Elfert A; El-Gohary Y; Keeffe EB
    Gastroenterology; 2009 Mar; 136(3):856-62. PubMed ID: 19135998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial.
    Huang JF; Yu ML; Huang CF; Chiu CF; Dai CY; Huang CI; Yeh ML; Yang JF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Wang LY; Chuang WL
    J Hepatol; 2011 Feb; 54(2):219-26. PubMed ID: 21056500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Santin M; Shaw E
    Lancet; 2002 Jan; 359(9302):263; author reply 264. PubMed ID: 11812596
    [No Abstract]   [Full Text] [Related]  

  • 27. [Peginterferon alfa-2a plus ribavirin for initial treatment of chronic hepatitis C in Korea].
    Lee H; Choi MS; Paik SW; Kim JH; Kim DY; Lee JH; Koh KC; Yoo BC; Rhee JC; Song SM
    Korean J Hepatol; 2006 Mar; 12(1):31-40. PubMed ID: 16565604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Picon PD; Costa AF; Kuchenbecker R; Beltrame A
    Lancet; 2002 Jan; 359(9302):263; author reply 264. PubMed ID: 11812597
    [No Abstract]   [Full Text] [Related]  

  • 29. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.
    Pearlman BL; Ehleben C
    Hepatology; 2010 Oct; 52(4):1519-20; author reply 1520-1. PubMed ID: 20879035
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
    Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Programs for continuing medical education: a session; 2. Current therapy for chronic hepatitis C].
    Imamura M; Chayama K
    Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):625-9. PubMed ID: 24796128
    [No Abstract]   [Full Text] [Related]  

  • 32. Occurrence of hepatocellular carcinoma was not a rare event during and immediately after antiviral treatment in Japanese HCV-positive patients.
    Kanda T; Imazeki F; Mikami S; Kato K; Shimada N; Yonemitsu Y; Miyauchi T; Arai M; Fujiwara K; Tsubota A; Takada N; Nishino T; Takashi M; Sugiura N; Kimura M; Fukai K; Yokosuka O
    Oncology; 2011; 80(5-6):366-72. PubMed ID: 21822027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Impact of age and sex on virologic responses of peginterferon alfa-2a and ribavirin treatment in chronic hepatitis C].
    Yu JW; Sun LJ; Kang P; Zhao YH; Yan BZ; Zhu PF
    Zhonghua Nei Ke Za Zhi; 2011 Dec; 50(12):1002-7. PubMed ID: 22333166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
    Shiffman ML; Ghany MG; Morgan TR; Wright EC; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Gretch DR
    Gastroenterology; 2007 Jan; 132(1):103-12. PubMed ID: 17241864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged therapy for hepatitis C with low-dose peginterferon.
    Hoshida Y; Golub TR
    N Engl J Med; 2009 Mar; 360(11):1152; author reply 1152-3. PubMed ID: 19283891
    [No Abstract]   [Full Text] [Related]  

  • 36. [Postoperative interferon therapy after resection of hepatitis C virus-related hepatocellular carcinoma].
    Katagiri S; Tokushige K; Yamamoto M
    Nihon Shokakibyo Gakkai Zasshi; 2008 Jun; 105(6):795-801. PubMed ID: 18525184
    [No Abstract]   [Full Text] [Related]  

  • 37. Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.
    Rivero-Juarez A; Lopez-Cortes LF; Girón-Gonzalez JA; Pineda JA; Rivero A;
    Lancet Infect Dis; 2014 Jan; 14(1):13-14. PubMed ID: 24355031
    [No Abstract]   [Full Text] [Related]  

  • 38. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
    Harrison SA; Hamzeh FM; Han J; Pandya PK; Sheikh MY; Vierling JM
    Hepatology; 2012 Aug; 56(2):464-73. PubMed ID: 22334369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Cecil BD
    Lancet; 2002 Jan; 359(9302):263-4. PubMed ID: 11812598
    [No Abstract]   [Full Text] [Related]  

  • 40. Progress on the treatment of hepatitis C.
    Nierengarten MB
    Lancet Infect Dis; 2003 Dec; 3(12):748. PubMed ID: 14664249
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.